Cyberonics Reports Positive Results From Extended ENCORE Study - Quick Facts

(RTTNews) - Cyberonics, Inc. (CYBX) announced results from the extension of the ANTHEM-HF clinical study, or ENCORE Study. The company said the results of the study show that Autonomic Regulation Therapy in patients with moderate to severe chronic heart failure and impaired heart function is well tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic heart failure.

Forty-nine patients previously enrolled in the ANTHEM-HF study elected to participate in the ENCORE study and received Autonomic Regulation Therapy for an additional 6 months.

Rohan Hoare, Chief Operating Officer of Cyberonics, said: "Based on the ANTHEM-HF and ENCORE study results, we plan to expand the commercial introduction of our VITARIA System in Europe and are in planning stages for additional clinical studies."